Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 20/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 20/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 20/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202199 | 0.85 | MAPK13 (0.58) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6202205 | 0.85 | MAPK14 (0.74) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6202228 | 0.81 | MAPK14 (0.70) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6202225 | 0.81 | MAPK14 (0.70) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6202073 | 0.79 | MAPK14 (0.50) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4849163 | 0.77 | MAPK13 (0.90) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6201603 | 0.75 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6204867 | 0.75 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6204078 | 0.75 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6202797 | 0.75 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427727-B1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6821971-B2 | FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA | THE PROCTER & GAMBLE COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | IL1B, IL1A, TNF | MAPK13 2109/4885MAPK12 2598/4885MAPK11 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.